证券代码：301166 证券简称：优宁维 公告编号：2025-087 上海优宁维生物科技股份有限公司 第四届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、会议召开情况 上海优宁维生物科技股份有限公司（以下简称"公司"）第四届董事会第九次 会议（以下简称"本次会议"）于 2025 年 10 月 28 日以现场结合通讯方式召开。 会议通知已于 2025 年 10 月 20 日以电子邮件方式送达全体董事。会议应出席的 董事 9 人，实际出席会议的董事 9 人。本次会议由董事长冷兆武先生主持，公司 高管列席会议。本次会议的召集、召开和表决程序符合法律、法规及《公司章程》 的规定。 二、会议审议情况 1、审议并通过《2025 年第三季度报告》 三、备查文件 1、公司第四届董事会第九次会议决议； 本议案已经公司董事会审计委员会审议通过。 2、审议并通过《关于计提资产减值准备的议案》 经审核，董事会认为：公司本次计提资产减值准备符合《企业会计准则》等 相关规定，计提相关资产减值准备依据充分，能够公允地反映公司财务状况、资 产价值及经营成果，使 ...

Financial Performance - The company's revenue for Q3 2025 was ¥271,231,009.48, a decrease of 1.45% compared to the same period last year[5] - The net profit attributable to shareholders was a loss of ¥1,699,666.95, representing a decline of 67.29% year-over-year[5] - Total operating revenue for Q3 2025 was CNY 776,063,650.82, a decrease of 6.25% from CNY 827,730,115.22 in the previous year[19] - Net profit for the period was a loss of CNY 15,079,551.28, compared to a profit of CNY 14,079,134.06 in the same period last year[20] - Basic and diluted earnings per share were both CNY -0.17, compared to CNY 0.16 in the previous year[20] Cash Flow - The net cash flow from operating activities was negative at ¥42,503,324.92, a significant decrease of 361.83% compared to the previous year[9] - Cash inflow from operating activities totaled CNY 877,071,606.82, a decrease from CNY 912,610,946.51 in the prior year[21] - The net cash flow from operating activities was -$42.5 million, a decrease from $16.2 million in the previous period[22] - The net cash flow from investment activities was -$422.5 million, compared to a positive $78.4 million in the prior period[22] - The net increase in cash and cash equivalents was -$496.9 million, contrasting with a positive increase of $35.4 million in the prior period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,223,819,725.65, down 3.71% from the end of the previous year[5] - Total assets decreased to CNY 2,223,819,725.65 from CNY 2,309,420,442.59, reflecting a decline of approximately 3.7%[18] - Total liabilities decreased to CNY 197,594,234.70 from CNY 241,515,885.28, a reduction of about 18.2%[18] - The company’s total equity attributable to shareholders was ¥2,026,225,490.95, down 2.02% from the previous year[5] - Shareholders' equity attributable to the parent company was CNY 2,026,225,490.95, down from CNY 2,067,904,557.31, a decrease of approximately 2%[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 9,893[10] - The largest shareholder, Leng Zhaowu, holds 33.09% of shares, totaling 28,674,000 shares[10] - The total number of restricted shares held by major shareholders at the end of the period is 29,748,000 shares[12] - The company plans to repurchase shares using between 25 million to 50 million RMB, with a maximum price of 45 RMB per share, within 12 months[13] - The company has repurchased a total of 927,600 shares, representing 1.07% of the total share capital, for a total payment of 25,987,076 RMB[13] Operational Costs and Expenses - Total operating costs amounted to CNY 811,539,307.02, down 3.4% from CNY 839,957,828.31 year-over-year[19] - Research and development expenses increased to CNY 47,613,035.52 from CNY 44,808,310.21, reflecting a growth of about 6.2%[19] - The company reported a decrease in financial expenses by 76.07%, attributed to reduced deposit interest[8] Cash and Cash Equivalents - As of September 30, 2025, the total cash and cash equivalents amount to 337,216,278.43 RMB, down from 840,157,413.87 RMB at the beginning of the period[16] - The ending balance of cash and cash equivalents was $335.0 million, down from $428.0 million at the end of the previous period[22] Other Information - The company has not yet audited its third-quarter financial report[23] - The company will implement new accounting standards starting in 2025[24]

Core Viewpoint - The company emphasizes its commitment to stabilizing stock prices through operational performance improvement and share repurchase initiatives, aligning with regulatory guidelines on market value management [1] Group 1: Share Repurchase Plans - The company has launched two share repurchase plans in 2024, with the first plan completed, utilizing 25,987,076 yuan to repurchase 927,600 shares [1] - The shares repurchased in the first phase are intended for employee stock ownership plans or equity incentives [1] - The second phase of the repurchase plan is currently in progress, with the first transaction completed on October 14, 2025, aimed at reducing registered capital [1] Group 2: Commitment to Investor Relations - The company is dedicated to enhancing investor communication as part of its strategy to maintain stable stock price fluctuations [1] - Future efforts will continue to focus on share repurchase and equity incentive tools to improve operational quality and performance, ultimately benefiting investors [1]

截至本报告披露日，于美玲女士未持有公司股票，王艳女士、杨洁女士分别 持有公司股东上海阳卓投资合伙企业（有限合伙）（持有公司 4,779,000 股股份， 为持有公司 5%以上股份的股东）0.90%份额、0.23%份额。 王艳女士、杨洁女士、于美玲女士离任后将继续严格遵守《深圳证券交易所 上市公司自律监管指引第 2 号—创业板上市公司规范运作》《深圳证券交易所上 市公司自律监管指引第 10 号—股份变动管理》等相关法律、法规、规范性文件 的规定；王艳女士在公司《首次公开发行股票并在创业板上市招股说明书》中所 作出的相关承诺也将继续履行。 公司对王艳女士、杨洁女士、于美玲女士在任职期间的勤勉工作及对公司发 展所作出的贡献表示衷心感谢！ 证券代码：301166 证券简称：优宁维 公告编号：2025-086 上海优宁维生物科技股份有限公司 关于监事离任的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 上海优宁维生物科技股份有限公司（以下简称"公司"）于 2025 年 9 月 28 日 召开第四届董事会第八次会议、第四届监事会第八次会议，于 2025 年 10 月 ...

法律意见书 上海市锦天城律师事务所 关于上海优宁维生物科技股份有限公司 2025 年第三次临时股东大会的 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海优宁维生物科技股份有限公司 2025 年第三次临时股东大会的法律意见书 致：上海优宁维生物科技股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受上海优宁维生物科技股 份有限公司（下称"优宁维"或"公司"）的委托，就公司召开 2025 年第三次 临时股东大会（以下简称"本次股东大会"）的有关事宜，根据《中华人民共和 国公司法》（以下简称"《公司法》"）、《上市公司股东会规则》等法律、法 规和其他规范性文件以及《上海优宁维生物科技股份有限公司章程》（以下简称 "《公司章程》"）的有关规定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实 ...

证券代码：301166 证券简称：优宁维 公告编号：2025-085 上海优宁维生物科技股份有限公司 2025 年第三次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： （1）现场会议时间：2025 年 10 月 16 日（星期四）下午 14:30 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2025 年 10 月 16 日 9:15—9:25，9:30—11:30 和 13:00—15:00；通过深圳 证券交易所互联网投票系统的具体时间为：2025 年 10 月 16 日 9:15 至 15:00 期 间的任意时间。 2、会议召开地点：上海市浦东新区古丹路 15 弄 16 号 1 楼公司会议室 3、会议召开方式：现场表决和网络表决相结合的方式 4、会议召集人：上海优宁维生物科技股份有限公司（以下简称"公司"）董 事会 5、会议主持人：公司董事 ...

Core Viewpoint - The company announced a share buyback of 16,100 shares, representing 0.0186% of its total share capital, scheduled for October 14, 2025 [2] Group 1 - The buyback will be executed through a dedicated securities account via centralized bidding [2] - The announcement was made on the evening of October 14 [2]

证券代码：301166 证券简称：优宁维 公告编号：2025-083 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 上海优宁维生物科技股份有限公司（以下简称"公司"或"优宁维"）于 2025 年 2 月 17 日召开第四届董事会第三次会议和第四届监事会第三次会议，2025 年 3 月 7 日召开 2025 年第二次临时股东大会，审议通过了《关于使用闲置募集资 金及自有资金进行现金管理的议案》，同意公司及并表范围内的子孙公司在不影 响募集资金投资项目建设、不影响公司正常生产经营及确保资金安全的情况下， 使用不超过人民币 30,000 万元（含本数）的闲置募集资金及不超过人民币 150,000 万元（含本数）的自有资金进行现金管理，使用期限自 2025 年 3 月 9 日起 12 个月内有效。公司独立董事和保荐机构均发表了同意意见。具体内容详见公司分 别于 2025 年 2月 19 日和 2025年 3 月 8日刊载于巨潮资讯网（www.cninfo.com.cn） 的相关公告。 现将公司近日使用部分闲置自有资金进行现金管理的相关事宜公告如下： 注 1：公司与上 ...

Core Viewpoint - The company, Youniwei (301166.SZ), has initiated a share buyback program, indicating confidence in its stock value and commitment to returning capital to shareholders [1] Group 1: Share Buyback Details - The company repurchased a total of 16,100 shares through a centralized bidding transaction [1] - This repurchase represents 0.0186% of the company's total share capital [1] - The highest transaction price was 30.77 CNY per share, while the lowest was 30.46 CNY per share [1] - The total amount spent on the repurchase was 492,272.00 CNY, excluding transaction fees [1]

Group 1 - The company, Youniwei, announced a share buyback of approximately 16,100 shares, representing 0.0186% of its total share capital, at a maximum price of 30.77 CNY per share and a minimum price of 30.46 CNY per share, with a total transaction amount of about 490,000 CNY [1] - The funds for the share buyback are sourced from the company's own funds, and the buyback price did not exceed the proposed upper limit of 43.77 CNY per share [1] - As of October 14, 2025, the company's revenue composition is entirely from the wholesale industry, accounting for 100% [1] Group 2 - The company's market capitalization is currently 2.6 billion CNY [2]